Paper36763530
The human proton pump inhibitors inhibit Mycobacterium tuberculosis rifampicin efflux and macrophage-induced rifampicin tolerance.
Lake MA and 11 others. Proc Natl Acad Sci U S A, 2023. Cited by 26 papers, by iCite.
Cite this record
ConductScience Library. The human proton pump inhibitors inhibit Mycobacterium tuberculosis rifampicin efflux and macrophage-induced rifampicin tolerance. Papers, record 36763530. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36763530
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Mycobacterium tuberculosis | Major topic |
| Tuberculosis | Major topic |
| Humans | |
| Rifampin | |
| Proton Pump Inhibitors | |
| Antitubercular Agents | |
| Verapamil | |
| Macrophages | |
| Drug Tolerance | |
| Bacterial Proteins | |
| Microbial Sensitivity Tests |
Source PubMed
Grants10
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| U19 AI162598 | NIAID NIH HHS | United States | U19AI162598 | PubMed and NIH | NIH RePORTER |
| 211145/Z/18/Z | Wellcome Trust | United Kingdom | PubMed | PubMed | |
| 223103 | Wellcome Trust | United Kingdom | PubMed | PubMed | |
| U19 AI135976 | NIAID NIH HHS | United States | U19AI135976 | PubMed | NIH RePORTER |
| R01 AI146194 | NIAID NIH HHS | United States | R01AI146194 | PubMed and NIH | NIH RePORTER |
| R37 AI054503 | NIAID NIH HHS | United States | R01AI054503 | PubMed and NIH | NIH RePORTER |
| R01 AI054503 | NIAID NIH HHS | United States | R01AI054503 | PubMed and NIH | NIH RePORTER |
| R01 AI150826 | NIAID NIH HHS | United States | R01AI150826 | PubMed | NIH RePORTER |
| 223103/Z/21/Z | Wellcome Trust | United Kingdom | PubMed | PubMed | |
| R37AI054503 | NIH | NIH RePORTER |
References103
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35737799 | Tumor necrosis factor induces pathogenic mitochondrial ROS in tuberculosis through reverse electron transport. | Science | 2022 | https://conductscience.org/library/papers/35737799 | PubMed |
| 2 | 19325113 | Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. | Science | 2009 | https://conductscience.org/library/papers/19325113 | PubMed |
| 3 | 16279802 | Exploratory chemistry toward the identification of a new class of multidrug resistance reverters inspired by pervilleine and verapamil models. | J Med Chem | 2005 | https://conductscience.org/library/papers/16279802 | PubMed |
| 4 | 28201528 | Pharmacoepidemiology for nephrologists: do proton pump inhibitors cause chronic kidney disease? | Nephrol Dial Transplant | 2017 | https://conductscience.org/library/papers/28201528 | PubMed |
| 5 | 21332993 | Ethidium bromide transport across Mycobacterium smegmatis cell-wall: correlation with antibiotic resistance. | BMC Microbiol | 2011 | https://conductscience.org/library/papers/21332993 | PubMed |
| 6 | 23245571 | New structure-activity relationship studies in a series of N,N-bis(cyclohexanol)amine aryl esters as potent reversers of P-glycoprotein-mediated multidrug resistance (MDR). | Bioorg Med Chem | 2013 | https://conductscience.org/library/papers/23245571 | PubMed |
| 7 | 18770603 | Genetic Manipulation of Mycobacterium tuberculosis. | Curr Protoc Microbiol | 2007 | https://conductscience.org/library/papers/18770603 | PubMed |
| 8 | 17416489 | Permeation of permanently positive charged molecules through artificial membranes--influence of physico-chemical properties. | Eur J Pharm Sci | 2007 | https://conductscience.org/library/papers/17416489 | PubMed |
| 9 | 22232275 | Functional and genetic characterization of the tap efflux pump in Mycobacterium bovis BCG. | Antimicrob Agents Chemother | 2012 | https://conductscience.org/library/papers/22232275 | PubMed |
| 10 | 32974492 | Cell wall inhibitors increase the accumulation of rifampicin in Mycobacterium tuberculosis. | Access Microbiol | 2019 | https://conductscience.org/library/papers/32974492 | PubMed |
| 11 | 11557355 | Structure-activity relationships and optimisation of the selective MDR modulator 2-(3,4-dimethoxyphenyl)-5-(9-fluorenylamino)-2-(methylethyl) pentanenitrile and its N-methyl derivative. | Bioorg Med Chem | 2001 | https://conductscience.org/library/papers/11557355 | PubMed |
| 12 | 35263517 | Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children. | N Engl J Med | 2022 | https://conductscience.org/library/papers/35263517 | PubMed |
| 13 | 12068801 | Mystery of multidrug transporters: the answer can be simple. | Mol Microbiol | 2002 | https://conductscience.org/library/papers/12068801 | PubMed |
| 14 | 31152740 | Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. | Gastroenterology | 2019 | https://conductscience.org/library/papers/31152740 | PubMed |
| 15 | 21376383 | Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. | Cell | 2011 | https://conductscience.org/library/papers/21376383 | PubMed |
| 16 | 12121966 | Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. | Antimicrob Agents Chemother | 2002 | https://conductscience.org/library/papers/12121966 | PubMed |
| 17 | 33951360 | Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. | N Engl J Med | 2021 | https://conductscience.org/library/papers/33951360 | PubMed |
| 18 | 26980498 | Morphological changes and differentially expressed efflux pump genes in Mycobacterium tuberculosis exposed to a rifampicin and verapamil combination. | Tuberculosis (Edinb) | 2016 | https://conductscience.org/library/papers/26980498 | PubMed |
| 19 | 30920070 | The association between proton pump inhibitor use and the risk of tuberculosis: A case-control study. | Pharmacoepidemiol Drug Saf | 2019 | https://conductscience.org/library/papers/30920070 | PubMed |
| 20 | 18310137 | Thioridazine and chlorpromazine inhibition of ethidium bromide efflux in Mycobacterium avium and Mycobacterium smegmatis. | J Antimicrob Chemother | 2008 | https://conductscience.org/library/papers/18310137 | PubMed |
Cited by17
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 26 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42708030 | Beyond acid suppression: the multifaceted role of proton pump inhibitors in Helicobacter pylori eradication. | Front Microbiol | 2026 | https://conductscience.org/library/papers/42708030 | PubMed |
| 42344733 | CRISPRi-mediated silencing of the ABC transporter Ms_5779 compromises cell envelope integrity and impairs intracellular host lipid exploitation. | Front Microbiol | 2026 | https://conductscience.org/library/papers/42344733 | PubMed |
| 42038188 | Comparison of Energy and Frequency of Nanosecond Q-switched ND-YAG Laser and Chlorhexidine on Reducing the Number of Oral Streptococcus Mutans Isolates: In Vitro Study :. | Galen Med J | 2025 | https://conductscience.org/library/papers/42038188 | PubMed |
| 41961393 | Integrated computational and experimental approaches for drug repurposing targeting key Mycobacterium tuberculosis proteins. | Mol Divers | 2026 | https://conductscience.org/library/papers/41961393 | PubMed |
| 41303606 | Verapamil Suppresses the Development of Resistance Against Anti-Tuberculosis Drugs in Mycobacteria. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41303606 | PubMed |
| 40697410 | A potent phenylalkylamine disrupts mycobacterial membrane bioenergetics and augments bactericidal activity of bedaquiline. | iScience | 2025 | https://conductscience.org/library/papers/40697410 | PubMed |
| 40572115 | Antimicrobial and Anti-Efflux Machinery of FDA-Approved Proton Pump Inhibitors and Vitamins Against Klebsiella pneumoniae and Pseudomonas aeruginosa. | Microorganisms | 2025 | https://conductscience.org/library/papers/40572115 | PubMed |
| 40331858 | Bedaquiline does not enhance a clofazimine-azithromycin-ethambutol regimen against Mycobacterium avium in the hollow-fiber system. | Antimicrob Agents Chemother | 2025 | https://conductscience.org/library/papers/40331858 | PubMed |
| 40244664 | Verapamil and its metabolite norverapamil inhibit the Mycobacterium tuberculosis MmpS5L5 efflux pump to increase bedaquiline activity. | Proc Natl Acad Sci U S A | 2025 | https://conductscience.org/library/papers/40244664 | PubMed |
| 39446300 | Molecular Indicator for Distinguishing Multi-drug-Resistant Tuberculosis from Drug Sensitivity Tuberculosis and Potential Medications for Treatment. | Mol Biotechnol | 2025 | https://conductscience.org/library/papers/39446300 | PubMed |
| 39364170 | A virulence-associated small RNA MTS1338 activates an ABC transporter CydC for rifampicin efflux in Mycobacterium tuberculosis. | Front Microbiol | 2024 | https://conductscience.org/library/papers/39364170 | PubMed |
| 39315396 | Photothermal and host immune activated therapy of cutaneous tuberculosis using macrophage targeted mesoporous polydopamine nanoparticles. | Mater Today Bio | 2024 | https://conductscience.org/library/papers/39315396 | PubMed |
| 39219694 | Enhance the Antimycobacterial Activity of Streptomycin with Ebselen as an Antibiotic Adjuvant Through Disrupting Redox Homeostasis. | Drug Des Devel Ther | 2024 | https://conductscience.org/library/papers/39219694 | PubMed |
| 37983978 | A Dose-Finding Study to Guide Use of Verapamil as an Adjunctive Therapy in Tuberculosis. | Clin Pharmacol Ther | 2024 | https://conductscience.org/library/papers/37983978 | PubMed |
| 37834390 | Drug-Tolerant Mycobacterium tuberculosis Adopt Different Survival Strategies in Alveolar Macrophages of Patients with Pulmonary Tuberculosis. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37834390 | PubMed |
| 37256924 | Profile of Lalita Ramakrishnan. | Proc Natl Acad Sci U S A | 2023 | https://conductscience.org/library/papers/37256924 | PubMed |
| 36951140 | Redefining tuberculosis: an interview with Lalita Ramakrishnan. | Dis Model Mech | 2023 | https://conductscience.org/library/papers/36951140 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ABCB1 | 5243 | PubTator's text mining | https://conductscience.org/library/genes/5243 | NCBI Gene |
| ABCB6 | 10058 | PubTator's text mining | https://conductscience.org/library/genes/10058 | NCBI Gene |
| FLNB | 2317 | PubTator's text mining | https://conductscience.org/library/genes/2317 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36763530
GET https://conductscience.org/api/papers/v1/36763530/references?page=2